Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$17K, compared with -$5.91M a year earlier. Trailing-twelve-month gross profit was -$10.62M. Over 3 fiscal years it compounded at -84.1% a year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, down 83.0 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$17K or moves back toward the trailing-twelve-month quarterly average of -$2.65M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17K-128.8% QoQ
Last fiscal yearDec 2025
$59K-92.7% YoY
LTMMar 2026
-$10.62M-104.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+99.7%——
1 year-92.7%——
3-year CAGR-84.1%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
59K USD
Year-over-year change
-92.7%
4-year CAGR
-64.9%

Gross Profit vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -104.7% is the 7th highest of 8, against a peer median of +74.8%.
  • Gross profit amounts to 17996.6% of revenue for AVTX, versus a peer median of 87.8%.
AVTX Competitors
Gross Profit for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$270.54M USD+582.2%—116.4%
QTTBQ32 Bio Inc.LTM Mar 2026$53.38M USD+14926.4%+100.2%99.3%
XNCRXencor, Inc.LTM Jun 2026$45.46M USD-54.8%—43.3%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$45.25M USD+200.0%—50.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$6.39M USD+74.8%-31.4%76.3%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€0 EUR———
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
IMUXImmunic, Inc.LTM Mar 2026-$33K USD+50.0%——
IFRXInflaRx N.V.LTM Mar 2026-€7.23M EUR-142.9%—24646.3%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$10.62M USD-104.7%-84.1%17996.6%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding AVTX) —+74.8%+34.4%87.8%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.4M18.05M1.92M441K59K
Cost of Revenue1.49M3.43M1.28M(366K)0
Gross Profit3.91M14.62M640K807K59K
Gross Margin72.4%81.0%33.3%183.0%100.0%
Research & Development59.84M31.31M13.78M52.08M50.08M
Selling, General & Admin24.66M20.71M10.3M17.24M22.9M
Operating Expenses86.04M52.06M27.99M69.32M72.98M
Depreciation & Amortization1.66M166K158K169K344K
EBITDA(80.5M)(37.29M)(23.29M)(34.85M)(77.75M)
EBITDA Margin-1491.2%-206.6%-1210.3%-7901.6%-131779.7%
Operating Income(82.13M)(37.44M)(27.35M)(68.51M)(72.93M)
Operating Margin-1521.6%-207.4%-1421.6%-15535.6%-123601.7%
Interest Income0003.32M4.35M
Interest Expense2.39M4.17M3.42M00
Other Income / Expenses(2.41M)(4.19M)(4.18M)33.5M(5.17M)
Income Before Tax(84.55M)(41.63M)(31.53M)(35.02M)(78.09M)
Pre-Tax Margin-1566.2%-230.6%-1638.8%-7939.9%-132362.7%
Income Tax Expense(196K)28K14K114K165K
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Net Margin-1563.1%-230.8%-1639.5%-7965.8%-132642.4%
EPS (Basic)(2,330.66)(1,062.65)(113.58)(4.32)(5.84)
EPS (Diluted)(2,330.66)(1,062.65)(113.58)(3.26)(5.84)
Weighted Avg Shares36.19K39.2K277.73K8.13M13.4M
Weighted Avg Shares (Diluted)36.19K39.2K277.73K10.78M13.4M

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.